Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
Rebecca Ahrens Nicklas, Rare disease physician-scientist at the Children’s Hospital of Philadelphia, shared on LinkedIn:
”Excited to share our vision for how we scale personalized gene editing therapies.
We need formal clinical trials to critically evaluate these novel treatments and (hopefully) obtain formal approvals.
One major step to make this happen is regulatory innovation.
We thought it was essential that we share our FDA interactions with the rare disease community so that we can all learn together about how we will build the field of interventional genetics.”
Read the full article in AJHG.
Article: How to create personalized gene editing platforms: Next steps toward interventional genetics
Authors: Rebecca Ahrens Nicklas, Kiran Musunuru

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies
-
Jul 12, 2026, 06:12Precision in Antithrombotic Therapy at ISTH 2026 – The Lancet Haematology
-
Jul 11, 2026, 23:36Emmanuel J Favaloro: A Fresh Perspective on the Manual Tilt Tube Method for PT and INR Determination
-
Jul 11, 2026, 21:47Michelle Meyer: Working Together to Advance Stroke Prevention in Atrial Fibrillation
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US